Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioPort
Gaithersburg, MD, USAemergentbiosolutions.com ↗
- Ownership
- Private
- Employees
- ~1100
- Development stage
- Other
01
Overview
Emergent BioSolutions (formerly BioPort) is a leading provider of medical countermeasures for public health threats, owning the only FDA-licensed anthrax vaccines (BioThrax and CYFENDUS) and the opioid overdose reversal agent NARCAN. The company maintains a significant presence in the U.S. Strategic National Stockpile with products for smallpox, botulism, and Ebola.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- VaccineSmall moleculeMonoclonal antibodyAntibodyBiologic
- Industry
- Biotech
02
Partnerships
U.S. Department of Defense (DoD)Biomedical Advanced Research and Development Authority (BARDA)Centers for Disease Control and Prevention (CDC)National Institute of Allergy and Infectious Diseases (NIAID)
Beyond the preview
Go deeper on BioPort.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioPort.